AlphaThera Awarded NIH Grant to Target Pancreatic Cancer

AlphaThera and its partners, Integral Molecular and the University of Pennsylvania, were recently awarded an NIH/NCI SBIR Phase II grant totaling $1.7M over 2 years to work on the project titled “Generation of Antibody-Drug Conjugates by Proximity-based Sortase-mediated Ligation”. The grant was awarded to AlphaThera for the development of highly homogenous antibody drug conjugates (ADC) for the treatment of pancreatic cancer and to identify the optimal approach and lead ADC for continued development into a clinical therapeutic. This grant award is a continuation of the NIH SBIR Phase I grant awarded to AlphaThera for a highly-efficient method of developing site-specific Antibody-Drug conjugates. 

Read more about the grant news & project goals. 

AlphaThera is a Pennovation Center company that specializes in site-specific  antibody-labeling technology. The company has commercialized its technology into a variety of oYo-Link® antibody labeling reagents which are sold to researchers in biotechnology companies, universities, and pharmaceutical companies. Alongside its oYo-Link commercialization effort, the company has worked to develop its bioconjugation technology for clinical use with the support of the NIH/NCI.